Genetic Signatures: From $4.9m to $28m in annual revenues in just 3 years
Listen to ASX-listed Genetic Signatures CEO Dr John Melki talk to Matt Birney on the Bulls N’ Bears Report about Genetic Signatures’ remarkable hike in revenue from its test kit that can detect infectious diseases – including COVID-19.